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Introduction
One of the most common chromosomal abnormalities in acute myeloid leukemia (AML) is the reciprocal translocation t(8;21)(q22;q22) which involves the RUNX1 (AML1) and the ETO (RUNX1T1) genes and produces a Runx1-ETO fusion transcript that inhibit Runx1-dependent transcriptional regulation.
1,2 Although RUNX1-ETO translocations could act as initiating events in hematopoietic stem cells (HSCs), after which leukemia clonally evolve through the acquisition of secondary mutations, 3,4 the molecular mechanism and the cellular signals that drive the generation of the t(8;21) translocation remain to be elucidated.
Much has been learnt in recent years about the onset or development of AML from studies examining Runx1 expression or function, 5-8 however we are still far from a complete understanding of the cellular mechanisms controlling transcription of its translocation partner ETO. [9] [10] [11] Considering that Wnt/β-catenin plays essential roles during proliferation or differentiation of HSCs and that reactivation of β-catenin signaling is important for self-renewal of leukemia stem cells, 12-14 we studied whether Wnt/β-catenin signaling was involved in ETO expression and RUNX1-ETO fusion.
Methods

Human CD34 + cells and cell lines
CD34 + cells were isolated from umbilical cord blood samples after normal full-term delivery from the Maternity Service at Complejo Asistencial Barros Luco (Santiago, Chile).
Informed consent was obtained according with the Declaration of Helsinki and the Ethics
Committee of the Universidad Andres Bello. KG1, HEK293 and L-cells secreting Wnt3a
were obtained from ATCC (Rockville, MD).
Cell culture conditions, Wnt/β-catenin signaling activity, semiquantitative and quantitative-PCR (qPCR), ETO promoter activity, plasmids and site-directed mutagenesis, β-catenin and RNAPII immunofluorescence, RNA-FISH and DNA-FISH experiments, image acquisition/processing and statistical analyses are described in Supplemental Methods.
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Results and Discussion
According to the current assembly of the human genome (GRCh38) the ETO gene consists of 17 exons distributed over 148 kb ( Figure 1A ) and its expression generates multiple mRNA isoforms by alternative splicing or the use of different promoters. or total ETO mRNA levels (3.6 fold, p=0.0028, n=6; Figure 1C ). Wnt3a effects on total ETO levels were further confirmed by Taqman analyses (2.9 fold, p=0.0011, n=7; Figure   1C and Supplementary Fig. 1 ). Finally, the effect of the signaling cascade on ETO expression was paralleled by enhanced transcription of Runx1 16, 17 (2.6 fold, p=0.0075, n=5) and classical target genes Axin2 and Myc (3.5 and 2.8 fold respectively, p=0.0075, n=5). 18, 19 Putative promoters for ETO-002 and -004 variants are located downstream of common RUNX1-ETO translocation hotspots ( Figure 1A ). To study if these promoters contained functional TBE sites, we PCR-cloned 890 and 2,459 nucleotides of the 5' upstream/exon 1 sequences of ETO-002 and -004, containing 6 and 7 potential TBE sites, respectively ( Figure 1D ). We also analyzed 1,535 nucleotides with 5 TBE sites upstream of the TSS described for variant ETO-009. 10 We observed a significant increase in the promoter
For personal use only. on April 12, 2017. by guest www.bloodjournal.org From activity of pETO-004 (2.5 kb) in HEK293 cells co-transfected for 24 h with increasing concentrations of constitutive active β-catenin (S33Y) ( Figure 1D ). Although basal transcription was observed for pETO-002 and pETO-009 promoters, no significant effects were found in cells co-transfected with these constructs and β-catenin S33Y (24 h). Then, we serially deleted potential TBE sites in pETO-004 (pETO-004-0.9 and pETO-004-04, respectively) and observed that these constructs responded accordingly to β-catenin stabilization or its inhibition by a dominant-negative ΔTCF4 construct ( Figure 1E 19.5 ± 2.7; p < 0.001; Supplementary Fig. 3A ), some of which clearly co-localized with active RNAPII foci ( Supplementary Fig. 3B,C) . Similar effects of β-catenin co-localization with RNAPII-Ser5 were observed in Wnt3a-treated KG1 cells ( Supplementary Fig. 4 ).
Our data indicates that β-catenin rapidly associates with RNAPII transcription factories in response to Wnt/β-catenin activation, further implying that expression of ETO and RUNX1 translocation partners could occur in these chromosomal structures. To address genes (intron 11 and 4, respectively) ( Figure 2C ). We noted that the total number of ETO and RUNX1 alleles expressed in control CD34 + cells increased from 25 to 54 after 4 h Wnt3a-treatment ( Supplementary Fig. 5 and Supplementary Table 2 ). Wnt/β-catenin induction was similarly observed for both genes (ETO alleles: from 9 to 21; RUNX1 alleles: from 16 to 33) and turned on the expression of a second allele in a greater number of cells. We determined the distance between RUNX1 and ETO alleles being simultaneously transcribed and observed that from a total of 105 Wnt3a-treated cells, 7 cells had distances < 300 nm between alleles (there were no events in the control setting that showed a proximity of less than 300 nm) and that the RNA signals in 3 of these CD34 + cells localized into the same chromosomal foci following activation of the cascade ( Figure   2C , Supplementary Fig. 5 ). Altogether, these observations confirm that Wnt/β-catenin enhances ETO and Runx1 expression in hematopoietic precursors and indicate that transcription of these genes is likely occurring into specialized nuclear factories. To further examine the hypothesis that Wnt signaling facilitates genomic proximity we performed DNA-FISH experiments in CD34 + cells and observed that RUNX1 and ETO genes are indeed brought up in close proximity (< 1 μm) after short-term Wnt3a treatment (4 h) (23% vs. 10%; Wnt3a vs. control conditions, respectively; Figure 2D and Supplementary Table   3 ). No significant differences in proximity were found between RUNX1 and ETO at 48 h, suggesting that an early transcriptional program commanded by the signaling cascade is involved in chromosome spatial organization and gene regulation.
Recent experiments indicate that β-catenin promotes genomic instability and T-cell transformation in mice by compromising DNA repair and enhancing illegitimate recombination. 24 Since most RUNX1-ETO translocations occur within of RUNX1-intron-5
and ETO-intron-7 we designed primers in RUNX1 exon 5 and ETO exon 8 to detect the product of the fusion of these genes. Notably, in CD34 + cells incubated with Wnt3a for 48 h we observed amplification of the expected RUNX1-ETO chimeric product ( Figure 2E and Supplementary Fig. 6 ). Finally, Wnt/β-catenin effects were further detected in HEK293 cells transfected for 48 h with increasing doses of β-catenin S33Y (Supplementary Fig. 7 ).
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Deregulation of Wnt/β-catenin signaling as a causative factor in leukemogenesis has become increasingly apparent.
12-14 Here we studied the transcriptional program directed by Wnt/β-catenin signaling in CD34 + and KG1 cells since they resemble normal human HSCs 15 and it has been suggested that immature cells, rather than committed progenitors, are the targets for leukemic transformation. 25 We observed that gain of function of Wnt/β-catenin signaling enhances transcription of ETO and RUNX1 translocation partners in genome organization centers within the nucleus, thereby increasing the potential for a chromosomal translocation event. To understand the role of Wnt/β-catenin signaling in other recurrent translocations remains as a question for further investigations.
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